CSL Limited  

(Public, ASX:CSL)   Watch this stock  
Find more results for ASX: CSL
145.68
+1.75 (1.22%)
Delayed:   3:10PM GMT+11
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 144.46 - 145.79
52 week 110.00 - 149.30
Open 144.48
Vol / Avg. 469,220.00/671,857.00
Mkt cap 65.89B
P/E 39.77
Div/yield 0.92/1.01
EPS 3.66
Shares 453.25M
Beta     -
Inst. own     -
Feb 14, 2018
Interim 2018 CSL Ltd Earnings Release Add to calendar
Jan 11, 2018
CSL Ltd at JPMorgan Healthcare Conference
Dec 5, 2017
CSL Ltd R&D Investor Meeting - Webcast
  

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin 16.35% 19.29%
Operating margin 19.46% 24.37%
EBITD margin - 29.70%
Return on average assets 12.30% 16.03%
Return on average equity 34.95% 46.67%
Employees 19,000 -
CDP Score - C

Address

45 Poplar Rd
MELBOURNE, VIC 3052
Australia
+61-3-93891911 (Phone)
+61-3-93891434 (Fax)

Website links

External links

Description

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Officers and directors

Paul Perreault Chief Executive Officer, Managing Director, Executive Director
Age: 60
David Mark Lamont Chief Financial Officer
Age: 52
Gordon Naylor President - Seqirus
Age: 54
Greg Boss Executive Vice President, Legal and CSL Group General Counsel
Age: 56
Karen Etchberger Executive Vice President - Quality and Business Services
Age: 59
Bob Repella Executive Vice President - Global Commercial Operations
Age: 58
Val Romberg Executive Vice President of Manufacturing and Planning
Age: 59
Alan J. Wills Senior Vice President - Strategy and Business Development
Age: 53
Andrew Cuthbertson Chief Scientific Officer, R&D Director
Age: 62
Laurie Reed Senior Vice President - Human Resources
Age: 53